MycoTeQ discovers and develops natural antibiotics against gram-negative bacteria. The pipeline of the company is based on natural small molecules produced by microfungi. A compound library representing microfungi from a range of biological niches forms the core of the discovery process.
Missing: MycoTeQ's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: MycoTeQ's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
MycoTeQ Frequently Asked Questions (FAQ)
When was MycoTeQ founded?
MycoTeQ was founded in 2006.
What is MycoTeQ's latest funding round?
MycoTeQ's latest funding round is Other Investors.
Who are the investors of MycoTeQ?
Investors of MycoTeQ include Novo Holdings and SEED Capital.
Who are MycoTeQ's competitors?
Competitors of MycoTeQ include Humanetics, Stemina Biomarker Discovery, Symphogen, Biovertis, Patheon and 13 more.
Compare MycoTeQ to Competitors
FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.
Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for to potentially treat a range of addictions located in the greater Boston, MA area.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.
FluGen is developing a universal influenza vaccine. The REDEE FLU influenza vaccine contains mutations in the M2 gene of the virus. The mutated virus can infect cells, express the entire spectrum of influenza RNA and proteins, yet fails to produce any infectious virus particles.
The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.